Article Versions Notes

Lin H-Y, Yu C-C, Chi C-L, Wei C-K, Yin W-Y, Tseng C-E, Li S-C. Peptidylarginine Deiminase Type 2 Predicts Tumor Progression and Poor Prognosis in Patients with Curatively Resected Biliary Tract Cancer. Cancers. 2023; 15(16):4131. https://doi.org/10.3390/cancers15164131

Lin, Hon-Yi, Chih-Chia Yu, Chen-Lin Chi, Chang-Kuo Wei, Wen-Yao Yin, Chih-En Tseng, and Szu-Chin Li. 2023. "Peptidylarginine Deiminase Type 2 Predicts Tumor Progression and Poor Prognosis in Patients with Curatively Resected Biliary Tract Cancer" Cancers 15, no. 16: 4131. https://doi.org/10.3390/cancers15164131

Lin, H.-Y., Yu, C.-C., Chi, C.-L., Wei, C.-K., Yin, W.-Y., Tseng, C.-E., & Li, S.-C. (2023). Peptidylarginine Deiminase Type 2 Predicts Tumor Progression and Poor Prognosis in Patients with Curatively Resected Biliary Tract Cancer. Cancers, 15(16), 4131. https://doi.org/10.3390/cancers15164131